Revvity, Inc. (NYSE:RVTY) Shares Sold by 2Xideas AG

2Xideas AG trimmed its stake in shares of Revvity, Inc. (NYSE:RVTY) by 38.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 88,381 shares of the company’s stock after selling 54,263 shares during the quarter. 2Xideas AG owned about 0.07% of Revvity worth $9,864,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in Revvity during the fourth quarter worth about $127,801,000. EdgePoint Investment Group Inc. increased its stake in Revvity by 34.6% in the third quarter. EdgePoint Investment Group Inc. now owns 2,685,775 shares of the company’s stock valued at $343,108,000 after purchasing an additional 690,534 shares during the last quarter. Proficio Capital Partners LLC lifted its holdings in shares of Revvity by 12,298.3% during the 4th quarter. Proficio Capital Partners LLC now owns 195,769 shares of the company’s stock worth $21,850,000 after acquiring an additional 194,190 shares during the period. ExodusPoint Capital Management LP purchased a new position in Revvity during the fourth quarter worth approximately $20,735,000. Finally, Vanguard Group Inc. boosted its holdings in Revvity by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 14,290,211 shares of the company’s stock valued at $1,594,930,000 after acquiring an additional 156,679 shares during the last quarter. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Revvity

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the sale, the insider now owns 33,400 shares of the company’s stock, valued at approximately $4,232,782. This represents a 31.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Tajinder S. Vohra sold 5,492 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the sale, the insider now owns 19,652 shares of the company’s stock, valued at approximately $2,295,550.12. This represents a 21.84 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.68% of the company’s stock.

Analyst Upgrades and Downgrades

RVTY has been the subject of several recent research reports. Bank of America raised shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price objective for the company in a research report on Friday, December 13th. KeyCorp increased their price objective on shares of Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Sanford C. Bernstein lowered shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price target for the company. in a research report on Friday, January 10th. Barclays raised their target price on Revvity from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Finally, Raymond James reiterated an “outperform” rating and issued a $145.00 price objective (up from $140.00) on shares of Revvity in a report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $136.25.

Revvity Stock Down 5.9 %

Shares of NYSE RVTY opened at $94.79 on Friday. The stock has a market cap of $11.39 billion, a P/E ratio of 42.89, a P/E/G ratio of 3.82 and a beta of 1.07. Revvity, Inc. has a 52-week low of $93.54 and a 52-week high of $129.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The firm has a 50 day moving average price of $113.18 and a 200 day moving average price of $116.49.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the prior year, the firm earned $1.25 earnings per share. Analysts expect that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be given a dividend of $0.07 per share. The ex-dividend date is Thursday, April 17th. This represents a $0.28 annualized dividend and a yield of 0.30%. Revvity’s dividend payout ratio (DPR) is presently 12.67%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.